Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: A randomized, open, prospective study

Neuropsychobiology

Volumn 54, Issue 4, 2007, Pages 247-251

  Lim, Hyun Kook ^a   Pae, Chi Un ^a   Lee, Chul ^a   Lee, Chang Uk ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Amisulpride; Behavioral and psychological symptoms of dementia; Dementia of the Alzheimer type; Risperidone

Indexed keywords

AMISULPRIDE; RISPERIDONE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AGED; ALZHEIMER DISEASE; ARTICLE; BARNES AKATHISIA RATING SCALE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MENTAL DISEASE; NEUROPSYCHIATRIC INVENTORY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIMPSON ANGUS RATING SCALE; SOMNOLENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SEVERITY OF ILLNESS INDEX; SULPIRIDE; TIME FACTORS;

EID: 34147109771     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100779     Document Type: Article

References (21)

1. Cohen-Mansfield J, Billig N: Agitated behaviours in the elderly. I. A conceptual review. J Am Geriatr Soc 1986;36:7-12.
2. Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K: The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257-263.
3. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychotic agitation of dementia. J Clin Psychiatry 2003;64:134-143.
4. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765.
5. Condren RM, Cooney C: Use of drugs by old age psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia. Aging Ment Health 2001;5:235-241.
6. Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1101-1111.
7. Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T: Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001;44:41-46.
8. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48:10-16.
9. Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, US Department of Health, Education, and Welfare Government Printing Office, 1976, pp 223-244.
10. Park JH, Kwon YC: Modification of the Mini-Mental State Examination for use in the elderly in a non-western society. I. Development of Korean version of Mini-Mental State Examination. Int J Geriatr Psychiatry 1990;5:381-387.
11. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45:11-19.
12. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
13. Duran JC, Greenspan A, Diago JI, Gallego R, Martinez G: Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. Int Psychogeriatr 2005;17:591-604.
14. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W; Amisulpride Study Group: Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999;88:107-117.
15. Legangneux E, McEwen J, Wesnes KA, Bergougnan L, Miget N, Canal M: The acute effects of amisulpride (50 and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol 2000;14:164-171.
16. Vaiva G, Thomas P, Llorca PM, Dupont S, Cottencin O, Devos P, Mazas O, Rascle C, Steinling M, Goudemand M: SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res Neuroimaging 2002;115:37-48.
17. Coulouvrat C, Dondey-Nouvel L: Safety of amisulpride (Solian®): a review of 11 clinical studies. Int Clin Psychopharmacol 1999;14:209-218.
18. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M; Risperidone Study Group: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115.
19. McKeage K, Plosker GL: Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004;18:933-956.
20. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943.
21. US Food and Drug Administration: FDA Public Health Advisory: deaths with anti-psychotics in elderly patients with behavioral disturbances. 2006. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm (accessed November 13, 2006).